China Resources Boya Bio pharmaceutical Group Co Ltd

China Resources Boya Bio-pharmaceutical Group's controlled subsidiary, Dalad Banner Boya Plasma Collection Co., Ltd., has obtained a Plasma Collection License from the Health Commission of Inner Mongolia Autonomous Region, granting approval to operate. The station is located in Dalad Banner, Ordos City, Inner Mongolia, with a collection area limited to the Dalad Banner region. Its business scope covers the collection and supply of source plasma, and the license is valid from July 17, 2026 to July 16, 2028. The company stated that obtaining the license and approval to operate will help enhance its source plasma supply capacity and have a positive impact on its long-term development.

China Resources Boya Bio-pharmaceutical Group's human von Willebrand factor has received a renewed drug clinical trial approval notice from the National Medical Products Administration on July 20, 2026, following an upgrade to its core manufacturing process. The product is intended for treating spontaneous and trauma-induced bleeding in adult and adolescent patients with von Willebrand disease. It first obtained clinical trial approval in August 2021, and the process upgrade was subsequently carried out to enhance product quality stability and clinical safety, with a new application submitted in April 2026. As of the announcement date, cumulative R&D investment in the project is approximately 41 million yuan. Currently, no similar product independently developed by a domestic company has been approved for marketing in China. The company stated that this approval will strengthen its pipeline for rare bleeding disorders, but the project remains in the clinical stage and will not have a significant impact on its 2026 operating results.